(Q36498799)

14 August 2017

1 reference

title

New strategies in chronic myeloid leukemia (English)

1 reference

14 August 2017

chronic myeloid leukemia

0 references

1

Hagop M Kantarjian

1 reference

14 August 2017

2

Jorge Cortes

1 reference

14 August 2017

1 May 2006

1 reference

International Journal of Hematology

14 August 2017

1 reference

14 August 2017

83

1 reference

14 August 2017

289-293

1 reference

14 August 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1532/ijh97.06024

14 August 2017

0 references

cites work

Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571).

1 reference

12 December 2020

Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib

1 reference

12 December 2020

Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells

1 reference

12 December 2020

Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies

1 reference

12 December 2020

ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent.

1 reference

12 December 2020

A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia

1 reference

12 December 2020

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

1 reference

12 December 2020

Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL--expressing cells, demonstrating synergy between AG490 and STI571.

1 reference

12 December 2020

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

1 reference

12 December 2020

A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells

1 reference

12 December 2020

Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.

1 reference

12 December 2020

Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts

1 reference

12 December 2020

Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells

1 reference

12 December 2020

Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia

1 reference

12 December 2020

Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs

1 reference

12 December 2020

Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies

1 reference

12 December 2020

BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90.

1 reference

12 December 2020

Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases

1 reference

12 December 2020

Overriding imatinib resistance with a novel ABL kinase inhibitor

1 reference

12 December 2020

SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice

1 reference

12 December 2020

Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase

1 reference

12 December 2020

Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase

1 reference

12 December 2020

Specific inhibition of bcr-abl gene expression by small interfering RNA.

1 reference

12 December 2020

A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance

1 reference

12 December 2020

Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial

1 reference

12 December 2020

Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib

1 reference

12 December 2020

Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia

1 reference

12 December 2020

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

1 reference

12 December 2020

Critical role for Gab2 in transformation by BCR/ABL

1 reference

12 December 2020

Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro

1 reference

12 December 2020

Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses

1 reference

12 December 2020

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

12 December 2020

Identifiers

DOI

10.1532/IJH97.06024

1 reference

PubMed ID

16757426

Dimensions Publication ID

14 August 2017

0 references

1 reference

PubMed ID

16757426